Search Results

 

 

Fellowship Programs

 ACCREDITATION

The Medical Toxicology Fellowship program at the Rocky Mountain Poison and Drug Center (RMPDC) has been training physicians since 1976. During this time, we have trained approximately 90 medical and clinical toxicologists. Our fellowship program set the standard for such training and has been responsible for the education of numerous leaders in the field. The fellowship is a two-year program during which the fellow is given ample opportunities to publish and gain valuable hands-on experience in toxicology.

The fellowship is located at the RMPDC, the busiest and one of the oldest poison centers in the US. A division of the Denver Health and Hospital Authority, the RMPDC has been in operation since 1956. The RMPDC is RMPDC is certified as a regional poison center by the American Association of Poison Control Centers. Our primary service area encompasses Colorado, Montana, Hawaii, and Nevada, and though physician phone consultations can extend nationwide. The RMPDC handles approximately 90,000 human exposure calls per year, of which approximately 3,500 involve direct input from the medical toxicology physicians. The fellowship is operated through the Denver Health Medical Center, a Level 1 regional trauma center within Denver Health and in conjunction with its emergency Medicine Residency.

Our medical toxicology fellows provide direct patient care at Denver Health Medical Center, the University of Colorado Hospital, and Children’s Hospital of Colorado. Fellows play a major role in providing education in toxicology to other physicians in emergency medicine, pediatrics and internal medicine departments within the Denver area as well as those who rotate with us from around the nation and the world.

The RMPDC toxicology fellowship program has been continually accredited by the Accreditation Council for the Graduate Medical Examination (ACGME) since July 1, 2000. Graduates of the fellowship are eligible to take the subspecialty examination in Medical Toxicology which is approved by the American Board of Medical Specialties. The sponsoring boards for this examination are the American Board of Emergency Medicine, the American Board of Pediatrics, and the American Board of Preventive Medicine.

ELIGIBILITY
All applicants must be medical school graduates (MD or DO degree) and have completed an ACGME or ACGME-I accredited primary residency program. Board-eligible physicians in any primary discipline of medicine are encouraged to apply. A Colorado medical license (full or in-training) and current DEA certification are also required.

Applicants who cannot meet these requirements, such as international fellows, may be able to participate in the International (non-ACGME) track (see below).

APPLICATION
RMPDC will be participating in the Medical Toxicology National Residency Match Program. Applications will be accepted between June 1 and September 30 for the year preceding the start (for example, applications to start in July 2015 should be submitted between June 1 and September 30, 2014). We have a limited number of interview opportunities, so applicants are encouraged to apply early as these spots fill quickly.

The RMPDC has a long tradition of training active duty military physicians in medical toxicology. Our program makes accommodations for military physicians who cannot participate in the NRMP and/or who cannot complete training on the usual July – June schedule. Please contact the program directly (MedToxFellowship@RMPDC.org).

 

The application procedure is quite simple and consists of:

  1. A letter requesting consideration for a program position,
  2. Three letters of recommendation including one from your residency director, and
  3. Current curriculum vitae.

Please submit applications to:

Eric Lavonas M.D.
Medical Toxicology Fellowship Program
Rocky Mountain Poison and Drug Center - Denver Health
777 Bannock Street, Mail Code 0180
Denver, CO 80204
MedToxFellowship@RMPDC.org

GOALS AND RESPONSIBILITIES

In keeping with the ACGME Program Requirements for Graduate Medical Education in Medical Toxicology, the fellowship has established its primary goals for the fellowship:

1)    Developing excellent clinical skills in the diagnosis and management of acute and chronic poisoning, including:

a)    Patient assessment

b)    Exposure assessment, including workplace exposures

c)    Appropriate use and interpretation of laboratory and other diagnostic testing

d)    Patient management, including supportive care, decontamination, enhanced elimination, and antidote administration

2)    Developing excellent understanding of pharmacology, including:

a)    Pharmacokinetics and toxicokinetics

b)    Mechanism of action of toxicants and therapies

3)    Developing excellent teaching skills at all levels, including medical and other health professional trainees, colleagues, and the lay public

4)    Developing the ability to lead and support exposure prevention programs in the workplace and community

5)    Developing  the ability to conduct independent research that is valid, insightful, useful, and ethical

6)    Developing skills related to population health, epidemiology, and biostatistics

7)    Developing administrative skills, such as may be required to direct a regional poison center, including the ability to design and execute quality improvement projects

8)    Obtaining sufficient knowledge to successfully complete the medical toxicology subspecialty board certification exam.

 

The curriculum is designed to cover the entire 2012 Core Content in Medical Toxicology over a 24-month period.

 

Responsibility of the Fellowship to the Fellow:

The responsibility of the Medical Toxicology Fellowship at the RMPDC to the fellow is to provide all the opportunities necessary to ensure that the goals of the fellowship are met and that the curriculum is simultaneously structured and flexible.

 

The primary educational components of the fellowship are:

 

1)    Direct patient care with graduated supervision

a)    Consultations in the hospital and emergency department

b)    Medical toxicology clinic

2)    Medical toxicology clinical support to the poison center, with graduated supervision

3)    Daily case conference and teaching rounds (2 hours, 5 times per week)

4)    Fellow-specific small group teaching sessions (approximately 5 hours per week)

5)    Mentored research projects

6)    Mentored topic reviews

7)    Special educational events, including educational site visits, journal clubs, and visiting professor events

 

In addition, the program encourages and supports fellow participation in several externally-based educational activities:

 

1)    Educational meetings

a)    North American Congress of Clinical Toxicology

b)    American College of Medical Toxicology Annual Scientific Meeting

c)    Western Toxicology Fellows’ meeting (an annual collaboration with the medical toxicology fellowship programs in Phoenix, Portland, Sacramento, San Diego, and San Francisco)

d)    Additional national or international meetings, based on special interest and needs

2)    National web-based educational sessions

a)    ACMT National Case Conference and National Journal Club, and Grand Rounds Webinars

b)    AACT National Journal Club

 

We believe in collaborative learning. Fellows are expect to work with, collaborate with, and learn from all of the nurses, pharmacists, Specialists in Poison Information, biostatisticians, research design specialists, basic scientists, and administrators in our organization.

CURRICULUM AND COURSES

The clinical toxicology fellowship is a two-year program, with progressive and graduated responsibility as fellows’ skill develops:

First Year—The first-year fellow is primarily responsible for:

  1. Being the primary on-call physician for the RMPDC, including
    1. Assessing and treating patients at Denver Health Medical Center, the   University of Colorado Hospital, and Children’s Hospital of Colorado
    2. Providing real-time clinical support to the RMPDC, including direct consultation with physicians
      1. RMPDC Specialists in Poison Information are nurses with at least a bachelor's degree and two years of critical care experience. They, therefore, usually consult the physicians only for the more interesting or seriously ill patients.
  2. Teaching students and residents who rotate through the poison center and assigning duties commensurate with their level of training.
    1. At the present time, emergency medicine residents from Denver Health Medical Center and other emergency medicine residencies throughout the United States as well as Fellows in Pediatric Emergency Medicine rotate through the poison center year-round.
  3. Participating in daily case review conferences in which recent cases referred to the poison center are discussed by the staff.
  4. Learning to expertly manage cases of general public concern, including mass exposure and hazardous material spills, and to write press releases and position statements when appropriate.
  5. Identifying areas of controversy and importance in toxicology which will become subjects of clinical or laboratory research in the fellow’s second year.
  6. Submitting case reports or series to peer review medical journals of toxicological importance to the medical community.
    1. Numerous opportunities for publication of textbook chapters and collective reviews are also available.
  7. Participating in the Poison Center Quality Assurance Program in which information provided by the poison center is reviewed. Our goal is to ensure that complete documentation and accurate advice is provided for every consult. 
  8. Becoming skilled in all areas identified in the section entitled "Goals of the Toxicology Fellowship." This should clearly define the first year as an exciting "learning" period.

 

Second Year—The second-year fellow is primarily responsible for:

  1. Being the on-call physician for the RMPDC, as above.
  2. Providing backup coverage for the first-year fellow during regular business hours.
  3. Conducting research and publishing the results in areas of interest identified in the first year.
    1. One complete original and comprehensive clinical or laboratory research manuscript is required.
  4. Continuing and extending the teaching responsibilities of the first year.
  5. Demonstrating leadership in the training program and its activities.
  6. Developing the administrative skills required to direct a regional poison center.
    1. One complete quality assurance project is required.
  7. Further developing clinical skills managing the critically ill toxicology patient, with attention to subtle, unusual, and highly complex presentations.
  8. Continuing to develop writing skills and abilities necessary to critically review the scientific literature.
  9. Leading chart and hospital rounds along with the attending. 
  10. Preparing to pass for the Medical Toxicology board exam at the end of the fellowship.

International Fellows and Other Non-ACGME Trainees

The RMPDC values interactions with our international colleagues and supports the development of medical toxicology in other countries. Physicians from outside the US who are not eligible for the ACGME-accredited fellowship training program are welcome, with the following structure:

International fellows do not generally provide direct patient care or provide real-time clinical support to the RMPDC. Physicians who qualify for the ACMGE pathway (successful completion of an ACGME or ACGEM-I accredited primary residency program, able to obtain a Colorado medical license (regular or in-training) and a DEA certificate) should apply through the ACGME pathway.

In general, international fellows and other non-ACGME trainees participate in one of two tracks:

1)    International Fellows

a)    Fixed duration of training: 12 or 24 months

b)    Must have completed the equivalent of a primary residency program

i)      In the UK MMC system, entitled to enter the Specialist or GP register

c)    Must be fully fluent in English, including the ability to read and right scientific English

d)    Duties and expectations identical to those of fellows in the ACGME program, except that they do not provide direct patient care, provide clinical support to the poison center, or take call

 

2)    Visiting International Scholars

a)    Variable duration of training, up to 2 months

b)    Must have completed medical school (MD, DO, or international equivalent degree)

c)    Must be proficient in English

d)    Participate in all educational activities of the fellowship program. Completion of research and quality assurance projects is encouraged but not required.

 

Students currently enrolled in medical school can rotate through the RMPDC as below.

 

International fellows and other non-ACGME trainees are not employed by Denver Health, and are therefore responsible for their own support and for tuition of US$1,500 per month. This amount is waived for training programs of less than 2 months duration (i.e. for Visiting International Scholars) and may be greatly reduced for trainees from low income countries (we use the World Bank list as a guide).

 

To the greatest extent possible, we align the academic year of International Fellows with that of ACGME-accredited fellowship program (July 1 – June 30).  The application requirement and deadlines are the same as for the accredited fellowship, and applicants will receive notice in December.

 

Visiting International Scholars may apply any time; application review and scheduling are on a rolling basis.

 

In general, the program will permit no more than 2 International Fellows and 1 – 2 Visiting International Scholars at any given time. Working through the University of Colorado, we can provide J-1 visa support for International Fellows. We are unable to provide significant visa assistance for Visiting International Scholars.

 

Residents, Students and Non-Physician Trainees

We accept the following trainees:

1)    Residents enrolled in an ACGME or ACGME-I accredited primary residency or subspecialty training program.

2)    Medical students

a)    Students sign up for an elective rotation (EMED 8024) through the University of Colorado School of Medicine

b)    Priority is given to CUSOM students

c)    Students from other medical schools, including international medical students, must register through the CUSOM (information can be found here)

3)    Pharmacy students and Pharmacy residents

4)    Students in Nurse Practitioner and Physician’s Assistant programs

5)    International medical trainees (students and physicians who do not meet the criteria for International Fellows or Visiting International Scholars)

6)    Other students by special request

Except by special arrangement, trainees in this group come for one month and are expected to produce an end-of-rotation presentation.

Please contact MedToxFellowship@rmpdc.org for more information.

Clinical Toxicology Fellowship Program

The RMPDC does not currently offer a Clinical Toxicology fellowship program. The American Academy of Clinical Toxicology maintains a list of these programs here.

Post-Doctoral Fellowship Program

The RMPDC does not currently offer post-doctoral fellowship positions in the basic sciences. Candidates with a PhD degree seeking such training are encourage to contact the University of Colorado Skaggs School of Pharmacy, the Division of Clinical Pharmacology and Toxicology, Department of Medicine, University of Colorado School of Medicine, or the Toxicology Graduate Program at the Colorado State University College of Veterinary Medicine and Biomedical Sciences to discuss opportunities.

Program Faculty

The medical toxicology fellowship program is supported by the following faculty members:

Medical Toxicologists:

• Jeffrey Brent, MD, PhD

    o Toxicology Associates, Denver

• Alvin Bronstein, MD

    o Medical Director, Rocky Mountain Poison Center, RMPDC

• Jennie Buchanan, MD

    o Department of Emergency Medicine, Denver Health Medical Center

• Ted Cetaruk, MD

    o Toxicology Associates, Denver

• Richard Dart, MD, PhD

    o Director, RMPDC

• Ben Hatten, MD
    o Toxicology Associates, Denver

    o Section of Medical Toxicology, Department of Emergency Medicine, University of Colorado School of Medicine (CUSOM)

• Kennon Heard, MD, PhD

    o Chief, Section of Medical Toxicology, Department of Emergency Medicine, CUSOM

• Jason Hoppe, DO

    o Section of Medical Toxicology, Department of Emergency Medicine, CUSOM

• Christopher Hoyte, MD
    o Director, Medical Toxicology Clinic, University of Colorado Anschutz Medical Campus

    o Section of Medical Toxicology, Department of Emergency Medicine, CUSOM

• Katie Hurlbut, MD
    o RMPDC

    o Department of Emergency Medicine, Denver Health Medical Center

• Janetta Iwanicki, MD
    o RMPDC

    o Department of Emergency Medicine, Denver Health Medical Center

• Michael Kosnett, MD

    o Division of Clinical Pharmacology and Toxicology, Department of Medicine, CUSOM

• Ken Kulig, MD

    o Toxicology Associates, Denver

• Eric Lavonas, MD

    o Program Director, Medical Toxicology Fellowship, and Associate Director, RMPDC

• Andrew Monte, MD

    o Section of Medical Toxicology, Department of Emergency Medicine, CUSOM

• Scott Phillips, MD

    o NewFields

• Barry Rumack, MD (retired)

    o Director Emeritus, Rocky Mountain Poison and Drug Center

• G. Sam Wang, MD
    o Director, Medical Toxicology service, Children’s Hospital of Colorado
    o Section of Emergency Medicine, Department of Pediatrics, CUSOM

    o Section of Medical Toxicology, Department of Emergency Medicine, CUSOM

• Luke Yip, MD
    o Department of Veterans Affairs, Ann Arbor, MI

 

Our medical toxicology attending physicians are board-certified or board-prepared in medical toxicology.

 

Clinical Toxicologists:

• Shireen Banerji, PharmD
    o RMPDC
• Rob Palmer, PhD
    o Toxicology Associates, Denver

 

Our clinical toxicologists are Diplomates of the American Board of Applied Toxicology.

 

Research Professionals:

 

       •   Becki Bucher-Bartelson, PhD
               o   Biostatistics Director, RMPDC
       •   Greg Bogdan, PhD
               o   Administrative Director, RMPDC
       •   Jody Green, PhD
              o   Director of Research Administration, RMPDC

 

Administrative support for the fellowship program is provided by:

      •   Melinda Malamoco, MS, Program Coordinator
      •   Darlene Vigil, Clerical Support Specialist

 

CURRENT FELLOWS

Senior Fellows

Dazhe (James) Cao MD graduated from Rice University and the Baylor College of Medicine. He completed an emergency medicine residency at Carolinas Medical Center, where he was chief resident, and is now board certified in emergency medicine. Dr. Cao is the recipient of the 2012 Emergency Medicine Foundation / Medical Toxicology Foundation Research Award. Dr. Cao currently serves as a Board Intern for the ACMT.

Sahaphume Srisuma MD (International Fellow) completed medical school at Ramathibodi Hospital, Bangkok, Thailand, internship at Phra Nakhon Si Ayutthaya Hospital, Phra Nakhon Si Ayutthaya, Thailand, and internal medicine residency training at Ramathibodi Hospital, Mahidol University, Bangkok. He is currently on a 2-year leave from his position on the faculty of the Division of Clinical Pharmacology and Toxicology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok to complete the RMPDC medical toxicology fellowship program.

Junior Fellows

Evan Poncher MD graduated from Loyola University and the Rush Medical College. He completed emergency medicine residency at North Shore University Hospital.

Elizabeth (Elise) ter Haar MD graduated from the University of California, Davis, and the University of California Irvine School of Medicine. She completed an emergency medicine residency at the University of Wisconsin.

ALUMNI

We are in the process of updating our alumni list.

RESEARCH AT RMPDC

The RMPDC operates a busy and highly productive academic research organization, staffed by a team of approximately 40 professionals. This includes dedicated teams for clinical trials, pharmacovigilance, database management, the RADARS System, and biostatistics. We have strong relationships with Clinical and Translational Sciences Institute at the University of Colorado Anschutz Medical Campus, and participate actively in The REDCap Consortium. Our investigators have a long track record of successful funding from government, foundation, and industry sources.

Fellows participate actively in research endeavors at the RMPDC, including all clinical trials conducted at Denver Health, the University of Colorado Hospital, and Children’s Hospital of Colorado. All fellows complete Good Clinical Practice (GCP) training through the Collaborative Institutional Training Initiative (CITI) during their first month of fellowship. 

A list of recent research publications by RMPDC authors below (faculty and fellows in bold):

2013

Anderson VE, Coulter MS, Sun J, Green JL, Heard KJ. What your patients aren't reporting-comparing urine drug screen data to patient self-reported medication history. Clinical Toxicology 2013;51:585-6.

Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy 2013;33:195-209.

Bronstein AC, Buscema M, Esfahani A, Lodwick WA, Grossi E. Locating the source of public health events using intelligent adaptive systems: 2011 United States listeriosis outbreak linked to whole cantaloupes. Clinical Toxicology 2013;51:625-6.

Brown KR, Severtson SG, Dart RC, Radars Syst Poison Ctr G. Intentional exposures to opioids reported by health care workers. Clinical Toxicology 2013;51:716-.

Bruhn SM, Ebbecke M, Bronstein AC, Spyker DA. A Comparison of Ciguatera Poisoning in the US and the EU. Clinical Toxicology 2013;51:630-.

Buchanan J, Windels D, Druck J, Heard K. Assessment of toxicology knowledge in fourth year medical students: 3 years of data. Clinical Toxicology 2013;51:689-90.

Buchanan JA, Eberhardt A, Tebb ZD, Heard K, Wendlandt RF, Kosnett MJ. Massive human ingestion of orpiment (arsenic trisulfide). The Journal of Emergency Medicine 2013;44:367-72.

Bucher-Bartelson B, Bailey JE, and Lowenstein S. Teen prescription drug use and abuse update. Brown University Child & Adolescent Behavior Letter 2013;29:3-4.

Bucher-Bartelson B, Bailey JE, and Lowenstein S. RADARS: Teen prescription drug use and abuse update. Brown University Child & Adolescent Psychopharmacology Update 2013;15:5-6.

Burghardt LC, Ayers JW, Brownstein JS, Bronstein AC, Ewald MB, Bourgeois FT. Adult Prescription Drug Use and Pediatric Medication Exposures and Poisonings. Pediatrics 2013;132:18-27.

Celentano A, Sesana F, Milanesi G, Davanzo F, Deutsch CM, Bronstein AC, Spyker DA. Unit dose liquid laundry detergent exposures: An italian and a US poison center comparison. Clinical Toxicology 2013;51:606-7.

Dargan PI, Green JL, Le Lait MC, Wood DM. Misuse of opioid containing prescription and over the counter medications in the United Kingdom. Clinical Toxicology 2013;51:341-.

Dart RC, Bogdan G, Heard K, Bucher-Bartelson B, Garcia-Ubbelohde W, Bush S, Arnold T, Clark RC, Hendey GW, Holstege C, Spradley EA. A Randomized, Double-Blind, Placebo-Controlled Trial of a Highly Purified Equine F(ab)2 Antibody Black Widow Spider Antivenom. Annals of Emergency Medicine 2013;61:458-67.

Dart RC, Bucher-Bartelson B, Adams EH. Non-medical Use of Tapentadol Immediate Release by College Students. The Clinical Journal of Pain 2013.

Dasgupta N FC, Brownstein JS, Menone CM, Surratt HL, Poppish L, Green JL, Lavonas EJ, Dart RC. Crowdsourcing black market prices for prescription opioids. Journal of Medical Internet Research 2013;15:e178.

Davis JM, Severtson SG, Bucher-Bartelson B, Dart RC. Using poison center exposure calls to predict prescription opioid abuse and misuse-related emergency department visits. Pharmacoepidemiology and Drug Safety 2013.

Deutsch CM, Bronstein AC, Lewis G. Don't drink the water: poison center and public health collaborate to manage a salmonella Event. Clinical Toxicology 2013;51:584-.

Lavonas EJ. Management of the critically poisoned patient. In Yealy DM, Callaway CW [Eds.], Emergency Department Critical Care. New York: Oxford University Press, 2013. pp. 105-15.

Fischer LJ, Poppish L, Le Lait MC, Bartelson BB, Dart RC, Radars System Poison Center Program Investigators. Geographic description of opioid exposures in pregnant women within the US. Clinical Toxicology 2013;51:718.

Fitzgerald KT, Bronstein AC. Adderall® (Amphetamine-Dextroamphetamine) Toxicity. Top Companion Anim Med 2013;28:2-7.

Fitzgerald KT, Bronstein AC. Selective Serotonin Reuptake Inhibitor Exposure. Top Companion Anim Med 2013;28:13-7.

Fitzgerald KT, Bronstein AC. Polyurethane Adhesive Ingestion. Top Companion Anim Med 2013;28:28-31.

Fitzgerald KT, Bronstein AC, Newquist KL. Marijuana Poisoning. Top Companion Anim Med 2013;28:8-12.

Froberg BA, King KJ, Kurera TD, Monte AA, Prosser JM, Walsh SJ, Riffenburgh RH, Rusyniak DE, Tanen DA. Negative Predictive Value of Acetaminophen Concentrations Within Four Hours of Ingestion. Academic Emergency Medicine 2013;20:1072-5.

Galvao TF, Silva MT, Silva AW, Bronstein AC, Pereira MG. Quality guidelines for poison centers: A systematic review. Clinical Toxicology 2013;51:303-.

Gerardo CJ, Evans CS, Kuchibhatia M, Drake WG, Mando-Vandrick JD, Yen M, Kopec KT, Lavonas EJ. Time to Antivenom Administration in Snakebite. Annals of Emergency Medicine 2013;62:S44.

Giraudon I, Lowitz K, Dargan PI, Wood DM, Dart RC. Prescription opioid abuse in the United Kingdom. British Journal of Clinical Pharmacology 2013;76:823-4.

Bogdan GM. Poison Centers: Public Health's Information & Communication Partner. CDC Community of Practice; 2013.

Bogdan GM. Nurse Triage Line Project: Integrating Poison Control Centers with Public Health. ASTHO/NACCHO sponsored Community Stakeholders Planning Conferences. Seattle, WA; 2013.

Bogdan GM. Innovative Use of Nurse Triage Lines During an Influenza Pandemic: Update on a CDC Collaborative Initiative between Public Health, Poison Control Centers and Other Partners. Public Health Preparedness Summit. Atlanta, GA; 2013.

Bogdan GM. Anticipate Impacts of Marketing Programs on Medical Affairs. Left Coast Medical Communications. Foster City, CA; 2013.

Green JL, Bartelson BB, Desel H, Ochsenfahrt G, Sesana F, Milanesi G, Brown J, Gunja N, Dart RC. Trends in Intentional and Unintentional Prescription Opioid Exposures reported to Poison Centers (PC) in Australia, Germany, Italy, Switzerland and the United States, 2007-2012. Clinical Toxicology 2013;51:717-8.

Green JL, Desel H, Milanesi G, Sesana F, Brown JA, Gunja N, Kupferschmidt H, De Vries I, Campbell A, Thomas SHL, Thompson JP,  Severtson SG, Poppish, L, Gmerek B, Dart R. Unintentional pediatric opioid exposures as reported to the Global Toxicosurveillance Network (GTNet) from 2008-2010. Clinical Toxicology 2013;51:339-.

Green JL, Heard KJ, Reynolds KM, Albert D. Oral and Intravenous Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review and Meta-analysis. The western journal of emergency medicine 2013;14:218-26.

Heard K, Sun J, Green JL, Dart RC, Anderson VE. Acetaminophen-protein adducts during prolonged administration of 4 g/day of acetaminophen. Clinical Toxicology 2013;51:577-.

Hoppe JA, Houghland J, Yaron M, Heard K. Prescription history of emergency department patients prescribed opioids. The western journal of emergency medicine 2013;14:247-52.

Hoyte CO, Albert D, Heard KJ. The use of energy drinks, dietary supplements, and prescription medications by United States college students to enhance athletic performance. J Community Health 2013;38:575-80.

Iwanicki JL, Buchanan J, Heard K. Baby bites spider: An unusual route of black widow spider envenomation. Clinical Toxicology 2013;51:623-4.

Iwanicki JL, Heard K. Starfruit toxicity in the absence of renal insufficiency: A case report. Clinical Toxicology 2013;51:636-7.

Jacob J, Albert D, Heard K. Single-agent duloxetine ingestions. Human & experimental toxicology 2013;32:427-33.

Kao D, Bartelson BB, Khatri V, Dart R, Mehler PS, Katz D, Krantz MJ. Trends in Reporting Methadone-Associated Cardiac Arrhythmia, 1997-2011 An Analysis of Registry Data. Ann Intern Med 2013;158:735-+.

Katz DF, Sun J, Khatri V, Kao D, Bucher-Bartelson B, Traut C, Lundin-Martinez J, Goodman M, Mehler PS, Krantz MJ. QTc Interval Screening in an Opioid Treatment Program. Am J Cardiol 2013.

Koonin L BS, Cropley J, Simone K, Bogdan G. Planning for a coordinated network of nurse triage lines during an influenza pandemic: Critical role for poison control centers. Clinical Toxicology 2013;51:697.

Kosnett MJ, Wang G. Child resistant packaging for edible cannabis products: translating research to practice. Clinical Toxicology 2013;51:685-.

Larson A, Stidham T, Banerji S, Kaufman J. Seizures and Methemoglobinemia in an Infant After Excessive EMLA Application. Pediatr Emerg Care 2013;29:377-9.

Lavery SA, Le Lait MC, Bartelson BB, et al. Intentional exposures to prescription opioids in rural areas of the United States. Clinical Toxicology 2013;51:716-7.

Lavonas E, Bucher-Bartelson B, Severtson S, et al. Abuse and diversion of immediate-release prescription opioids: 30 months of data from the RADARS (R) System. J Pain 2013;14:S58-S.

Lavonas EJ, Khatri V, Daugherty C, Bucher-Bartelson B, King T, Dart RC. Medically Significant Late Bleeding After Treated Crotaline Envenomation: A Systematic Review. Ann Emerg Med 2013.

Lavonas EJ, Benson BA, Seifert SA. Failure to develop sensitization despite repeated administration of ovine Fab snake antivenom: Update of a single-patient, multicenter case series. Ann Emerg Med 2013;61:371-2.

Lavonas EJ, Banner W, Bradt P, Bucher-Bartelson B, Brown KR, Rajan P, Murrelle L, Dart RC, Green JL. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children. J Pediatr, 2013; 163(5):1377-83.

Lavonas EJ, Green JL, Severtson SG, Le Lait MC, Lowitz K, Poppish L, Dart RC. Changes in oxymorphone abuse rates following introduction of a crush-resistant formulation. Presented at the International Conference on Opioids, Boston, MA, June 9, 2013

Lavonas EJ, Severtson SG, Bucher-Bartelson B, Green JL, Cicero T, Kurtz SP, Rosenblum A, Surratt HL, Dart RC. Buprenorphine/Naloxone Film Diversion and Abuse Rates are Less than Tablet Formulations. J Addiction Med 2013;in press.

Law RK, Schier JG, Martin CA, Olivares DE, Thomas RG, Bronstein AC, Chang AS. National surveillance for radiological exposures and intentional potassium iodide and iodine product ingestions in the United States associated with the 2011 Japan radiological incident. Clin Toxicol 2013;51:41-6.

Maddry JK, Amir MK, Sessions D, Heard K. Fatal dabigatran toxicity secondary to acute renal failure. Am J Emerg Med 2013;31:462 e1-2.

Maddry JK, Breyer K, Cook KM, Heard K. Monomorphic ventricular tachycardia after intentional citalopram overdose. Am J Emerg Med 2013;31:447 e5-8.

Maddry JK, Heard K, Hoppe J, Sessions D. Utilization of online video to educate providers on use of gastric lavage for drug overdoses. Clinical Toxicology 2013;51:688-.

Miech R, Bohnert A, Heard K, Boardman J. Increasing use of nonmedical analgesics among younger cohorts in the United States: a birth cohort effect. J Adolesc Health 2013;52:35-41.

Monte AA, Ceschi A, Bodmer M. Safety of non-therapeutic atomoxetine exposures-a national poison data system study. Hum Psychopharmacol-Clin Exp 2013;28:471-6.

O'Malley RN, Heard KJ, Bronstein AC, Deutsch C, O'Malley GF. Accessing the poison center in the 21st century-How do patients find and contact their poison center? Clinical Toxicology 2013;51:701-.

Palmer R, Zumwalt R. Three autopsy cases with antemortem and postmortem blood fentanyl measurements. Clinical Toxicology 2013;51:616-7.

Pomerleau AC, Schauben JL, Bronstein AC, Chang AS. On the Role of Poison Centers in Radiation Emergency Preparedness and Response Activities: Findings of the "Radiation Emergencies Public Health Roundtable" (Atlanta, GA-August 2012). J Med Toxicol 2013.

Reynolds KM, Bartelson BB, Khatri V, Dart RC, Green JL. Accuracy of poison center data improves after targeted training. Clinical Toxicology 2013;51:703-4.

Seifert SM, Seifert SA, Schaechter JL, Bronstein AC, Benson BE, Hershorin ER, Arheart KL, Franco VI, Lipschultz SE. An analysis of energy-drink toxicity in the National Poison Data System. Clinical Toxicology 2013;51:566-74.

Sessions D, Heard K, Kosnett M. Fatal Cesium Chloride Toxicity After Alternative Cancer Treatment. J Altern Complement Med 2013.

Severtson S, Davis J, Le Lait M, Bucher-Bartelson B, Dart R. Use of both individuals filling prescriptions and population rates in assessing abuse potential of prescription opioids. J Pain 2013;14:S14-S.

Severtson SG, Bartelson BB, Davis JM, Munoz A, Schneider MF, Chilcoat H, Coplan PM, Surratt H, Dart RC. Reduced Abuse, Therapeutic Errors, and Diversion Following Reformulation of Extended-Release Oxycodone in 2010. J Pain 2013.

Sheikh S, Chang A, Kieszak S, Law R, Bennett HK, Ernst E, Bond GR, Spiller HA, Schurz-Rogers H, Chu A, Bronstein AC, Schier JC. Characterizing risk factors for pediatric lamp oil product exposures. Clin Toxicol 2013;51:871-8.

Smith SM, Dart RC, Katz NP, Paillard F, Adams EH, Comer SD, Degroot A, Edwards RR, Haddox JD, Jaffe JH, Jones CM, Kleber HD, Kopecky EA, Markman JD, Montoya ID, O'Brien C, Roland CL, Stanton M, Strain EC, Vorsanger G, Wasan AD, Weiss RD, Turk DC, Dworkin RH; Analgesic, Anesthetic, and Addiction Clinical Trials, Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership. Classification and definition of misuse, abuse, and related events in clinical trials: ACTTION systematic review and recommendations. Pain 2013.

Spyker DA, Banerji S, Bronstein AC. A case of the flu. Clinical Toxicology 2013;51:626-7.

Stauter E, Shuman C, Traut C, Zirakzadeh A, Bucher-Bartelson B. Tobacco Use Highly Prevalent in Prescription Opioid Abusers. Am J Addict 2013;22:310-.

Toschlog EA, Bauer CR, Hall EL, Dart RC, Khatri V, Lavonas EJ. Surgical Considerations in the Management of Pit Viper Snake Envenomation. J Am Coll Surg 2013.

Varney SM, Maddry JK, Bebarta VS, Thaxton RE, Ganem VJ, Zarzabal LA. A Comparison of Simulation-Based Education versus Lecture-Based Instruction for Toxicology Training in Emergency Medicine Residents. Annals of Emergency Medicine 2013;62:S154-S5.

Wang GS, Banerji S, Roussil TK, Heard KJ. Survival after amphotericin B overdose treated with plasmapheresis. Ann Pharmacother 2013;47:e9.

Wang GS, Deakyne S, Bajaj L, Yin S, Heard K, Roosevelt G. The limited utility of screening laboratory tests and electrocardiograms in the management of unintentional asymptomatic pediatric ingestions. The Journal of emergency medicine 2013;45:34-8.

Wang GS, Roosevelt G, Heard K. Pediatric marijuana exposures in a medical marijuana state. JAMA Pediatr 2013;167:630-3.

Winter EJ ME, Lavonas EJ, Bucher-Bartelson B, Poppish L, Green JL, Dart RC, RADARS® System Poison Center Program. Micromedex® clarification of Suboxone® products increases coding accuracy in the RADARS® System Poison Center Program. Clin Toxicol 2013;51:719.

Wittler M, Lavonas EJ. Antipsychotics. In Marx J, et. al. [Eds.]. Rosen’s Emergency Medicine: Concepts and Clinical Practice, 8th ed Philadelphia: Mosby; 2013.

Wood DM, Green JL, Le Lait MC, Dargan PI. Misuse of prescription benzodiazepines and non-prescription sedative hypnotics ('Z drugs') in the United Kingdom. Clinical Toxicology 2013;51:319-.

Wood DM, Green JL, Le Lait MC, Dargan PI. Is there evidence of misuse of Baclofen, Gabapentin and Pregabalin in the United Kingdom (UK)? Clinical Toxicology 2013;51:663-.

Zosel A, Bartelson BB, Bailey E, Lowenstein S, Dart R. Characterization of Adolescent Prescription Drug Abuse and Misuse Using the Researched Abuse Diversion and Addiction-Related Surveillance (RADARS (R)) System. J Am Acad Child Adolesc Psychiatr 2013;52:196-204.

Wang GS, Le Lait MC, Heard K. Unintentional pediatric exposures to central alpha-2 agonists reported to the National Poison Data System. J Pediatr 2013 Oct 1;doi:pii: S0022-3476(13)01066-4 10.1016/j.jpeds.2013.08.038 [Epub ahead of print].

2012

Banerji S, Wang, GS, Heard, K, Bronstein A. Plasmapheresis for Amphotericin B Overdose. The North American Congress of Clinical Toxicology (NACCT) National Conference. Las Vegas, NV; 2012.

Banerji S, Bronstein AC. Iatrogenic error: Survival after Amphotericin B overdose. Clinical Toxicology; 2012:600-1.

Banerji S, Larson AA, Bronstein AC. Triad of toxicity following topical application of EMLA. Clinical Toxicology; 2012:601-.

Bebarta VS, Maddry J, Borys DJ, Morgan DL. Incidence of tricyclic antidepressant-like complications after cyclobenzaprine overdose. Am J Emerg Med 2012;30:374.

Bennett C, Dy I, Wiernik P, Buchanan J, Dart RC, Edlin B, Gilbert E, Mahindra P, Murday A, Qureshi ZP. Cocaine-Levamisole Thrombovasculopathy: A Report From the Southern Network On Adverse Reactions (SONAR) Project. Blood 2012;120.

Bogdan G. Poison Control Centers: An Infrastructure for a Pandemic Nurse Triage Line. Public Health Preparedness Summit; 2012 February 23, 2012; Anaheim, CA; 2012.

Bogdan GM. Denver Health: On the Path to Preparedness. International Visitor Leadership Program – Public Health Issues in US. Denver, CO; 2012.

Bogdan GM. Poison Centers: As Pandemic Nurse Triage Lines. American Association of Poison Control Centers Symposium, North American Congress of Clinical Toxicology. Las Vegas, NV; 2012.

Bronstein AC, Wyke S, Spyker DA. Toward Harmonisation of National Poisons Information Service and National Poison Data System Reporting. Clinical Toxicology; 2012:294-5.

Brown KR, Severtson SG, Dart RC, RADARS® System Poison Center Group. RADARS® System poison center intentional exposures to OxyContin®: a look at the differences in rates of abuse via unintended routes before and after reformulation intervention. North American Congress of Clinical Toxicology (NACCT) Annual Meeting. Las Vegas, NV; 2012.

Brown KR, Severtson SG, Dart RC, RADARS® System Poison Center Group. RADARS system poison center intentional exposures to OxyContA look at the differences in rates of abuse via unintended routes before and after reformulation intervention. Clinical Toxicology; 2012:632-3.

Buchanan J, Lavonas EJ. Aganulocytosis and other consequences due to illicit cocaine contaminated with levamisole. Curr Opin Hematology; 2012:27-31.

Buchanan JA, Eberhardt A, Tebb ZD, Heard K, Wendlandt RF, Kosnett MJ. Massive Human Ingestion of Orpiment (Arsenic Trisulfide). The Journal of emergency medicine 2012.

Bucher Bartelson B, Severtson SG, Davis JM, Surratt H, Chilcoat H, Coplan P, Green JL, Dart RC. A comparison of the street price of original and reformulated extended release oxycodone product. International Association for the Study of Pain (IASP) Annual Meeting. Madison, WI; 2012.

Bucher-Bartelson B, Green JL, Desel H, Sesana F, Milanesi G, Gunja N, Brown J, Gmerek B, Dart RC. Intentional and Unintentional Prescription Opioid Exposures in Italy, Germany and the United States. Clinical Toxicology; 2012:680-1.

Buttke DE, Schier, J.G., Bronstein, A.C., Chang. A Characterization of Animal Exposure Calls Captured by the National Poison Data System, 2000-2010. . J Clinic Toxicol 2012;2:117.

Cima A, Valdez TN, Bronstein AC, Banerji S. Learning how to get legally high. Clinical Toxicology; 2012:630.

Dart R. Buprenorphine-naloxone as an abuse-deterrent drug. College on Problems of Drug Dependence Annual Meeting; 2012 June 14, 2012; Palm Springs, CA; 2012.

Dart RC. The Secret Life of America's Poison Centers. Annals of Emergency Medicine 2012;59:62-6.

Dart RC, Adams, E., Bucher-Bartelson, B., Baker, G., Pitner, J., Vorsanger, G. Trends in the non-medical use of tapentadol immediate release by college students. American Academy of Pain Medicine (AAPM) Annual Meeting. Palm Springs, CA; 2012.

Dart RC. RADARS® System Buprenorphine. College on Problems of Drug Dependence (CPDD) Annual Meeting. Palm Springs, CA; 2012.

Dart RC, Adams, E., Bucher-Bartelson, B., Baker, G., Pitner, J., Vorsanger, G. . Trends in the non-medical use of Nucynta by college students. PAINWeek 2012. Las Vegas, NV; 2012.

Dart RC. RADARS® System Abuse/Tamper Deterrent Formulations (California & National). California Society of Addiction Medicine (CSAM) Opioid Pre-Conference Workshop. San Francisco, CA; 2012.

Dart RC, Adams EH, Bucher-Bartelson BB, Baker GM, Pitner JK, Vorsanger GJ. Tapentadol abuse: the first 18 months. Pharmacotherapy 2012;32:E243-E.

Dart RC, Bronstein AC, Spyker DA. Consumer Exposure Calls to US Poison Centers. Clinical Toxicology; 2012:311-2.

Dart RC, Rumack BH. Intravenous acetaminophen in the United States: iatrogenic dosing errors. Pediatrics 2012;129:349-53.

Dart RC, Cicero TJ, Surratt HL, Rosenblum A, Bartelson BB, Adams EH. Assessment of the abuse of tapentadol immediate release: The first 24 months. J Opioid Manag 2012;8:395-402.

Dasgupta N, Davis, J., Funk, M.J., Dart, R. Using poison center exposure calls to predict methadone poisoning deaths. PLos ONE 2012;7:e41181.

Davis J, Severtson SG, Bartelson BB, Muñoz, A., Schneider, M.F., Surratt, H., Chilcoat, H., Coplan, P., Green, J.L., Dart, R.C. Changes in Diversion Rates Following the Introduction of a Reformulated Extended Release Oxycodone Product. Pharmacoepidemiology and Drug Safety; 2012:450-1.

Davis JM, Bucher-Bartelson, B., Severtson, S.G., Dart, R.C., RADARS® System Poison Center Group. Regional differences in seasonal trends in suicide exposures to prescription opioids as reported to poison centers participating in the RADARS® System. Clinical Toxicology; 2012:636.

Deutsch CM, Bronstein AC, Spyker DA. A spoonful of cinnamon: The "cinnamon challenge" - Google Trends and the National Poison Data System. Clinical Toxicology; 2012:645-.

Easter B, Buchanan JA. Images in Emergency Medicine: Varicella zoster virus (chicken pox) and varicella pneumonitis. Annals of Emergency Medicine 2012;60:146.

Emamhadi M, Sanaei-Azdeh, H., Nikniya, M., Zamani, N., Dart, R.C. Electrocardiographic manisfestations of tramadol toxicity with special reference to their ability for prediction of seizures. American Journal of Emergency Medicine 2012;30:1481-5.

Fischer LJ, Davis, J.M., Bucher-Bartelson, B., Poppish, L., Dart, R.C., RADARS® System Poison Center Group. Prescription opioid and stimulant use among pregnant women: surveillance by poison control centers participating in the RADARS® System. Clinical Toxicology; 2012:634-5.

Galvao TF, Silva EN, Silva MT, Bronstein AC, Pereira MG. Economic evaluation of poison centers: a systematic review. International journal of technology assessment in health care 2012;28:86-92.

Gormley NJ, Bronstein AC, Rasimas JJ, Pao M, Wratney AT, Sun J, Austin HA, Suffredini AF. The rising incidence of intentional ingestion of ethanol-containing hand sanitizers. Critical care medicine 2012;40:290-4.

Green JL. The impact of tamper resistant formulations on prescription drug abuse. National Association of State Controlled Substance Authorities (NASCA) Conference. Scottsdale, AZ; 2012.

Green JL, Bucher-Bartelson B, Desel H, Sesana F, Milanesi G, Gunja N, Brown J, Gmerek B, Dart RC. Intentional and unintentional prescription stimulant exposures in Italy, Germany and the United States. Clinical Toxicology; 2012:637-8.

Green JL, Dart RC, Reynolds KM, Pediatric Cough Cold Medication Safety Surveillance Group. Adverse events with cough/cold product use in children: Four years of surveillance. Clinical Toxicology; 2012:595-.

Green JL, Thomas SHL, Thompson JP, Kupferschmidt H, Desel H, Gunja N, Brown J A, Sesana F, Milanesi G, De Vries I, Dart RC. International Perspective of Prescription Opioid Exposures Reported to Poison Centres from 2007 – 2010. Clinical Toxicology; 2012:312.

Hahn SA, Lavonas EJ, Mace, S.E., Napoli, A.M., Fesmire, F.M. Clinical policy: critical issues in the initial evaluation and management of patients presenting to the emergency department in early pregnancy. Ann Emerg Med 2012;60:381-90. e28.

Heard K. Transaminase Elevations from Maximal Therapeutic Acetaminophen Dosing: Evidence from the “Up-and-Down” Study. American Association for the Study of Liver Diseases Clinical Research Single Topic Conference; 2012 June 10, 2012; Atlanta, GA; 2012.

Heard K, Bui A, Mlynarchek SL, Green JL, Bond GR, Clark RF, Kozer E, Koff RS, Dart RC. Toxicity From Repeated Doses of Acetaminophen in Children: Assessment of Causality and Dose in Reported Cases. Am J Ther 2012.

Heard K, Green J. Acetylcysteine Therapy for Acetaminophen Poisoning. Current pharmaceutical biotechnology 2012.

Heard K, Vogel J. Response to comment on dental pain as risk factor for accidental acetaminophen overdose: a case-control study. American Journal of Emergency Medicine 2012;30:511-.

Heppe DB, Bucher-Bartelson B, Estacio RO, Krantz MJ. Impact of cardiovascular disease guideline dissemination on provider knowledge. The American journal of the medical sciences 2012;343:56-60.

Hoyt C, Lavonas EJ. Salicylate poisoning. BMJ Point-of-Care 2012.

Hoyte CO, Cushing TA, Heard KJ. Anaphylaxis to black widow spider antivenom. Am J Emerg Med 2012;30:836 e1-2.

Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ. A Characterization of Synthetic Cannabinoid Exposures Reported to the National Poison Data System in 2010. Annals of Emergency Medicine 2012;60:435-8.

Hoyte CO, Jacob JE, Heard KJ. A Survey of Athletes and their Use of Performance Enhancing Substances. Clinical Toxicology; 2012:291.

Hoyte CO, Leikin JB. Management of diethylene glycol ingestion. Clin Toxicol 2012;50:525-7.

Jacob J, Albert DG, Hoyte C, Heard K. The Safety of Duloxetine in Overdose: A Poison Center Review. Clinical Toxicology; 2012:311.

Jacob J, Tarabar AF. A rare case of combined strychnine and propoxur toxicity from a single preparation. Clinical Toxicology 2012;50:224-.

Jacob J, Albert D, Heard K. Single-agent duloxetine ingestions. Human & experimental toxicology 2012;[Epub ahead of print].

Khatri V, Green JL, Dart RC, Albert D, Reynolds KM, Pediat Cough Cold Medication S. Multi-system pediatric cough/cold product surveillance methodology: Evaluation of data sources. Clinical Toxicology; 2012:670-1.

Lavergne V, Nolin TD, Hoffman RS, Roberts D, Gosselin S, Goldfarb DS, Kielstein JT, Mactier R, Maclaren R, Mowry JB, Bunchman TE, Juurlink D, Megarbane B, Anseeuw K, Winchester JF, Dargan PI, Liu KD, Hoegberg LC, Li Y, Calello DP, Burdmann EA, Yates C, Laliberté M, Decker BS, Mello-Da-Silva CA, Lavonas E, Ghannoum M.The EXTRIP (EXtracorporeal TReatments In Poisoning) workgroup: guideline methodology. Clinical Toxicology 2012;50:403-13.

Lavonas E. Antivenoms for snakebite: design, function, and controversies. Current pharmaceutical biotechnology; 2012.

Lavonas E. Coagulopathy: The most important thing we still don’t know about snakebite. [invited editorial. The western journal of emergency medicine; 2012.

Lavonas E. Toxicology. In Yealy D, Callaway C [Eds.]. Emergency Department Critical Care New York: Oxford University Press; 2012.

Lavonas EJ, Benson, J.E., Seifert, S.A. Failure to develop sensitization despite repeated administration of ovine Fab snake antivenom: update of a single-patient, multi-center case series. . Annals of Emergency Medicine 2012.

Lavonas EJ, Severtson, G., Murrelle, E.L., Ruby, J., Bucher-Bartelson, B., Dart, R.C. . Unintentional exposures to buprenorphine/naloxone tablets and oral film among children less than 6 years old. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) European Congress (Abstract published in Value Health). Berlin, Germany; 2012.

Lavonas EJ, Fries JF, Furst DE, Rothman KJ, Stergachis A, Vaida AJ, Zelterman D, Reynolds KM, Green JL, Dart RC. Comparative risks of non-prescription analgesics: a structured topic review and research priorities. Exp Opin Drug Saf, 2012; 11(1):33-44.

Lavonas EJ, Khatri V, Daugherty C. Medically Significant Late Bleeding Following Treated Crotaline Envenomation: A Structured Topic Review. Toxicon; 2012:226-.

Maddry J, Brozovich D, Heard K. Prolonged hypocalcemia refractory to calcium gluconate following ammonium bifluoride ingestion. Clinical Toxicology; 2012:601-2.

Maddry JK, Breyer K, Cook KM, Heard K. Monomorphic ventricular tachycardia after intentional citalopram overdose. Am J Emerg Med 2012.

Maddry JK, Monte A, Sessions D, Heard K. Fatal dabigatran toxicity secondary to acute renal failure. Am J Emerg Med 2012;doi:pii: S0735-6757(12)00409-3. 10.1016/j.ajem.2012.08.015. [Epub ahead of print].

Maremanni I, Green, J.L. Trends of opioid misuse and diversion: lessons for Europe from the USA. International Society of Addiction Medicine (ISAM) RBP Sponsored Symposium. Geneva, Switzerland; 2012.

Miech R BA, Heard K, Boardman J. Increasing use of nonmedical analgesics among younger cohorts in the United States: a birth cohort effect. J Adolesc Health 2012;52:35-41.

Monte AA. Black Widow Spider (Latrodectus mactans) Antivenom in Clinical Practice. Current pharmaceutical biotechnology 2012;13:1935-9.

Monte AA, Heard KJ, Vasiliou V. Prediction of drug response and safety in clinical practice. J Med Toxicol 2012;8:43-51.

Monte AA, Vasilou V, Heard KJ. Omics Screening for Pharmaceutical Efficacy and Safety in Clinical Practice. J Pharmacogenomics Pharmacoproteomics 2012;16:S5.

Reifler LM, Droz D, Bailey JE, , Schnoll SH, Fant R, Dart RC, Bucher-Bartelson B. Do Prescription Monitoring Programs Impact State Trends in Opioid Abuse/Misuse? Pain Medicine 2012;13:434-42.

Reynolds KM, Green JL, Dart RC, Bucher-Bartelson B, Khatri V. Overall quality of poison center data for acetaminophen-containing products is high, but coding of product-specific fields needs improvement. Clinical Toxicology; 2012:620-1.

Richards DB, Wang GS, Buchanan JA. Tea tree oil ingestion treated with surfactant. Clinical Toxicology; 2012:655-.

Rumack B, Heard, K., Green, J., Albert, D., Bucher-Bartelson, B., Bodmer, M., Sivilotti, M.L., Dart, R.C. . Effect of therapeutic doses of acetaminophen (up to 4 g/day) on serum alanine aminotransferase levels in subjects consuming ethanol: systematic review and meta-analysis of randomized controlled trials. Pharmacotherapy 2012;32:784-91.

Sande M, Thompson D, Monte AA. Fomepizole for severe disulfiram-ethanol reactions. American Journal of Emergency Medicine 2012;30:262.e3-.e5.

Schaeffer T, Khatri V, Reifler LM, Lavonas EJ. . Incidence of Immediate Hypersensitivity Reaction and Serum Sickness Following Administration of Crotalidae Polyvalent Immune Fab Antivenom: A Meta-analysis. Acad Emerg Med 2012;19:121-31.

Schaeffer TH. Fundamental Principles of Toxicology and Exposure. BP OneHealth; 2012; Tbilisi, GA; 2012.

Schaeffer TH. Fundamental Principles of Occupational Health. BP OneHealth; 2012; Tbilisi, GA; 2012.

Schaeffer TH. The risks of occupational exposure to sugarcane work, Brazil and beyond. Global Health Conference, BP OneHealth; 2012; Chicago, IL; 2012.

Schaeffer TH. Drugs and alcohol abuse in the workplace. BP OneHealth; 2012; London, England; 2012.

Schaeffer TH. Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics. Journal of Medical Toxicology 2012.

Schaeffer TH, Kokko, J., Lavonas, E.J. The rate of immediate hypersensitivity reactions and serum sickness following administration of crotalidae polyvalent immune fab antivenom - a meta-analysis. Academic Emergency Medicine 2012;19:121-31.

Seifert SA, White J, Currie BJ, Lavonas EJ. Pressure Bandaging with Immobilization in Crotalinae Envenomation Controversy. Toxicon; 2012:222-.

Sessions D, Kosnett M, Heard K. Fatal cesium chloride toxicity after subcutaneous administration of an oral preparation. Clinical Toxicology; 2012:640-.

Severtson SG, Bucher-Bartelson, B., Chilcoat, H., Coplan, P., Surratt, H., Dart, R.C. A comparison of the street price of original and reformulated OxyContin® and immediate release (IR) oxycodone products. American Pain Society (APS) Annual Meeting. Honolulu, HI; 2012.

Severtson SG, Bartelson BB, Davis J, Muñoz, A., Schneider, M.F., Coplan, P., Chilcoat, H., Green, J.L., Dart, R.C . Difference in Rates of Abuse Following Reformulation of Extended Release Oxycodone Using Data From the RADARS (R) System Poison Center Program. Annals of Emergency Medicine; 2012:S34-S5.

Severtson SG, Bartelson BB, Davis JM, Munoz A, Schneider MF, Coplan P, Chilcoat H, Green JL, Dart RC. Difference in Rates of Abuse Following Reformulation of Extended Release (ER) Oxycodone Using Data from the Radars (R) System Poison Center Program. Pharmacoepidemiology and Drug Safety; 2012:221-.

Spyker DA, Bronstein AC. National Poison Center Data System Carisoprodol Encounters 2000 – 2011. Clinical Toxicology; 2012:311.

Spyker DA, Gummin D, Spiller H, Bronstein AC. Population adjustment for US poison center call volume changes: 2000-2010. Clinical Toxicology; 2012:617-8.

Spyker DA, Thomas S, Bateman DN. Thompson J, Cooper G, Spears R, Bronstein AC. International trends in designer amphetamine abuse in UK and US, 2009-2012. Clinical Toxicology; 2012:636-7.

Surratt H, Kurtz, S.P., Cicero, T.J., Dart, R.C. Street prices of prescription opioids diverted to the illicit market. College on Problems of Drug Dependence (CPDD) Annual Meeting. Palm Springs, CA; 2012.

Turk DC, O'Connor, A.B., Dworkin, R.H., Chaudhry, A., Katz, N.P., Adams, E.H., Brownstein, J.S., Comer, S.D., Dart, R.C. Dasgupta, N. Richard A. Denisco, R.A., Klein, M., Leiderman, D.B., Lubran, R., Rappaport, B.A., Zacnym, J.P., Ahdieh, H., Burke, L.B., Cowan, P., Jacobs, P., Malamut, R., Markman, J. , Michna, E., Palmer, P., Peirce-Sandner, S., Potter, J.S., Raja, S.N., Rauschkolb, C., Roland, C.L., Webster, L.R., Weiss, R.D., Wolf, K. Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations. Pain 2012.

Valley MA, Heard KJ, Ginde AA, Lezotte DC, Lowenstein SR. Observational Studies of Patients in the Emergency Department: A Comparison of 4 Sampling Methods. Annals of Emergency Medicine 2012;60:139-45.

Varney SM, Bronstein, A.C. Using the National Poison Data System to Detect Mistaken Oral Ingestions of Medication Capsules Designed for Use in Pulmonary Inhalers. Hospital Pharmacy 2012;47:118-23.

Varney SM, Buchanan, J.A., Kokko, J., Heard, K. Acetylcysteine for acetaminophen overdose in patients who weigh >100 kg. Am J Ther 2012.

Wang GS, Deakyne, S., Bajaj, L., Yin, S., Heard, K., Roosevelt G. The Limited Utility of Screening Laboratory Tests and Electrocardiograms in the Management of Unintentional Asymptomatic Pediatric Ingestions. The Journal of emergency medicine 2012.

Wang GS, Banerji S., Roussil, K. Heard, K. . Survival After Amphotericin B Overdose Treated with Plasmapheresis. The Annals of Pharmacotherapy 2012.

Wang GS, Roosevelt, G., Heard, K. Pediatric Marijuana Exposures in a Medical Marijuana State. Archives of Pediatric and Adolescent Medicine 2012.

Wang GS, Heard K. Pediatric marijuana exposures in medical marijuana legal state. Clinical Toxicology; 2012:679.

Wang GS, Tham E, Maes J, Buchanan JA. Flecainide toxicity in a pediatric patient due to differences in pharmacy compounding. Int J Cardiol 2012.

Wang GS, Yin S, Shear B, Heard K. Severe poisoning after accidental pediatric ingestion of glycol ethers. Pediatrics 2012;130:e1026-9.

Weigand TJ, Gorodetsky RM, Green JL, Dart RC. Elevated Acetaminophen-Cysteine Adducts Facilitate Diagnosis of Acetaminophen Toxicity in a Case of Unexplained Acute Liver Failure. Clinical Toxicology; 2012:303.

Winter EJ, Davis, J.M., Bucher-Bartelson, B., Westberry, R., Green, J.L., Lavonas, E.J., Dart, R.C., RADARS® System Poison Center Group. Systematic misclassification in product-specific coding of poison center data: The example of buprenorphine in the RADARS system poison center program. Clinical Toxicology; 2012:633-.

Wolkin AF, Martin CA, Law RK, Schier JG, Bronstein AC. Using poison center data for national public health surveillance for chemical and poison exposure and associated illness. Ann Emerg Med 2012;59:56-61.

Yin S, Heard KJ. Complex suicide: self-incineration and acetaminophen overdose. Injury 2012;43:124-5.

 

 

 

Resources for Residents and Students

Gastric Lavage Tutorial (video cannot be accessed from Denver Health computers)